Carboplatin
Carboplatin is a platinum-based antineoplastic agent used across a wide range of solid tumors.
Carboplatin is a platinum-based antineoplastic agent used across a wide range of solid tumors. Like other platinum compounds it acts by forming DNA adducts, chiefly 1,2-intrastrand crosslinks between adjacent guanines, which distort the helix and block replication and transcription until the damage either is repaired or triggers apoptosis. It differs from cisplatin in the chemistry of its leaving group: the bidentate cyclobutanedicarboxylate departs far more slowly than cisplatin's chlorides, so the drug is less reactive, circulates longer and produces the same adducts more gradually. That single difference accounts for the clinical profile — substantially less nephrotoxicity, ototoxicity and emesis than cisplatin, at the cost of greater myelosuppression, with thrombocytopenia its most characteristic dose-limiting effect.
Because carboplatin is cleared almost entirely by glomerular filtration and its toxicity tracks total exposure rather than body size, it is dosed to a target area under the concentration-time curve calculated from renal function rather than by body surface area — an unusual practice among cytotoxics and the main safeguard against overdosing patients with impaired kidneys. Repeated exposure also produces a distinctive hypersensitivity that typically appears after several cycles rather than on first administration, often requiring desensitization in patients being retreated. Resistance develops through increased nucleotide excision repair and adduct tolerance, altered platinum influx and efflux, and inactivation by intracellular thiols.
In practice it is given in combination — with paclitaxel, pemetrexed, gemcitabine or etoposide, and increasingly with targeted and immune agents including pembrolizumab, durvalumab, atezolizumab, amivantamab and serplulimab. It is a standard backbone in lung cancer, gynecologic malignancies, breast cancer and pediatric or rare tumors; in ovarian cancer the interval between completing platinum and relapsing defines platinum sensitivity, which governs whether it is used again and what follows it. Carboplatin also appears in veterinary oncology and in experimental drug-delivery research.
Where the papers sit
15 papers from the last 6 months study carboplatin directly · updated from PubMed 16 Nov 2026
Study type 1 clinical trial · 4 observational · 2 human data · 7 preclinical · 1 unclassified
Themes 3 themes
-
Platinum Therapy Optimization
Platinum therapy research is shifting from describing carboplatin activity toward improving sensitivity, delivery and treatment selection. Apoptosis, autophagy, SMS1/SMS2 regulation and mitochondrial-immune signaling recur as explanations for response or resistance. Prodrugs, sonosensitizers, biomaterials and three-dimensional models seek more selective or effective exposure. Evidence remains largely preclinical and heterogeneous, so clinical benefit and economic value are still unresolved.
9 papers · 60%
-
Neoadjuvant Platinum Chemotherapy
Neoadjuvant carboplatin-taxane regimens are being adapted across cervical, head and neck, breast and salivary cancers. Paclitaxel remains central, while anthracycline-free treatment is being weighed against survival outcomes in triple-negative breast cancer. Cetuximab and HER2-directed therapy extend combination treatment beyond cytotoxic chemotherapy. Pregnancy, tumour subtype and real-world outcomes remain important constraints on regimen selection.
4 papers · 26.7%
-
EGFR-Mutant Lung Cancer
EGFR-mutated non-small-cell lung cancer is moving toward combination treatment after progression rather than chemotherapy alone. Ivonescimab plus chemotherapy is being tested against chemotherapy, with progression-free survival as a key endpoint. Amivantamab with carboplatin-pemetrexed is being refined through weight-tiered dosing. The central question is whether these combinations improve control after targeted-therapy failure without adding unacceptable treatment burden.
2 papers · 13.3%
Papers
The 15 papers from the last 6 months that study carboplatin directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Platinum Therapy Optimization (9)
- Integrative transcriptomic and network analysis elucidates the multi-target molecular mechanisms of carboplatin in melanoma. Medical oncology (Northwood, London, England) · 20 Oct 2026 PMID 42900432
- Carboplatin-derived dinuclear Pt(IV) prodrug linked by 1,6-Diaminohexane: Design, synthesis, reduction chemistry, DNA interaction, and antitumor activity. Bioorganic chemistry · 18 Oct 2026 PMID 42892156
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
- Repurposing Alzheimer's and ovarian cancer drugs as sonosensitizers for glioblastoma via a positive-unlabeled learning and 3D bioprinting-based new approach methodology (NAM). PloS one · 12 Aug 2026 PMID 42585241
- Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia. Journal of medical economics · 31 Jul 2026 PMID 42535775
- Integrative Multi-Omics Analysis Reveals a Mitochondrial-Immune Axis Associated With Neoadjuvant Chemotherapy Response in High-Grade Serous Ovarian Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 20 Jul 2026 PMID 42474029
- Synthesis and biological evaluation of 6,9-disubstituted purine analogues inducing autophagy-mediated apoptosis and potentiating carboplatin response in high-grade serous ovarian cancer. Bioorganic chemistry · 2 Jul 2026 PMID 42391813
- Theoretical insights into the activation of carboplatin and its interaction with DNA bases on magnesia: synergistic drug delivery and magnesium supplementation. Physical chemistry chemical physics : PCCP · 16 Jun 2026 PMID 42300117
- A microphysiological spheroid system for modeling glioblastoma structure and therapy response. Biochemical and biophysical research communications · 22 May 2026 PMID 42172901
Neoadjuvant Platinum Chemotherapy (4)
- Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Breast cancer research and treatment · 9 Sept 2026 PMID 42714613
- HER2-positive salivary duct carcinoma: durable response to targeted therapy and chemotherapy. BMJ case reports · 24 Aug 2026 PMID 42637511
- Neoadjuvant Paclitaxel-Carboplatin Chemotherapy Followed by Cesarean Radical Hysterectomy in Pregnant Patients With Cervical Cancer: Obstetric, Neonatal, and Surgical Outcomes. The journal of obstetrics and gynaecology research · 23 Jul 2026 PMID 42489393
- Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373242
EGFR-Mutant Lung Cancer (2)
- Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology · 24 Aug 2026 PMID 42636833
- Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer. CPT: pharmacometrics & systems pharmacology · 21 May 2026 PMID 42166539
By study type
Clinical trials (1)
- Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology · 24 Aug 2026 PMID 42636833
Observational studies and case reports (4)
- Anthracycline-containing versus anthracycline-free carboplatin-based regimens in early-stage triple-negative breast cancer: real-world outcomes. Breast cancer research and treatment · 9 Sept 2026 PMID 42714613
- HER2-positive salivary duct carcinoma: durable response to targeted therapy and chemotherapy. BMJ case reports · 24 Aug 2026 PMID 42637511
- Neoadjuvant Paclitaxel-Carboplatin Chemotherapy Followed by Cesarean Radical Hysterectomy in Pregnant Patients With Cervical Cancer: Obstetric, Neonatal, and Surgical Outcomes. The journal of obstetrics and gynaecology research · 23 Jul 2026 PMID 42489393
- Neoadjuvant Chemotherapy With Paclitaxel, Carboplatin, and Cetuximab for Locally Advanced Head and Neck Cancer. Anticancer research · 29 Jun 2026 PMID 42373242
Human data, design not indexed (2)
- Estimating the budget impact of introducing dostarlimab as first line in treating endometrial cancer in Saudi Arabia. Journal of medical economics · 31 Jul 2026 PMID 42535775
- Development of the Weight-Tiered Q3W Regimen of Amivantamab in Combination With Carboplatin-Pemetrexed in EGFR-Mutated Non-Small Cell Lung Cancer. CPT: pharmacometrics & systems pharmacology · 21 May 2026 PMID 42166539
Preclinical: animal, cell and lab studies (7)
- Integrative transcriptomic and network analysis elucidates the multi-target molecular mechanisms of carboplatin in melanoma. Medical oncology (Northwood, London, England) · 20 Oct 2026 PMID 42900432
- Carboplatin-derived dinuclear Pt(IV) prodrug linked by 1,6-Diaminohexane: Design, synthesis, reduction chemistry, DNA interaction, and antitumor activity. Bioorganic chemistry · 18 Oct 2026 PMID 42892156
- SMS1 and SMS2 differentially regulate platinum chemotherapy sensitivity in ovarian cancer cells. Molecular biology reports · 13 Aug 2026 PMID 42593674
- Repurposing Alzheimer's and ovarian cancer drugs as sonosensitizers for glioblastoma via a positive-unlabeled learning and 3D bioprinting-based new approach methodology (NAM). PloS one · 12 Aug 2026 PMID 42585241
- Synthesis and biological evaluation of 6,9-disubstituted purine analogues inducing autophagy-mediated apoptosis and potentiating carboplatin response in high-grade serous ovarian cancer. Bioorganic chemistry · 2 Jul 2026 PMID 42391813
- Theoretical insights into the activation of carboplatin and its interaction with DNA bases on magnesia: synergistic drug delivery and magnesium supplementation. Physical chemistry chemical physics : PCCP · 16 Jun 2026 PMID 42300117
- A microphysiological spheroid system for modeling glioblastoma structure and therapy response. Biochemical and biophysical research communications · 22 May 2026 PMID 42172901
Unclassified: not yet indexed with MeSH (1)
- Integrative Multi-Omics Analysis Reveals a Mitochondrial-Immune Axis Associated With Neoadjuvant Chemotherapy Response in High-Grade Serous Ovarian Cancer. Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 20 Jul 2026 PMID 42474029
Written from 15 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-11 by GPT. Corrections: 2026-08-08 by GPT. Drafted by language models from published abstracts; not medical advice.